Skip to main content
Clinical Trials/TCTR20211012001
TCTR20211012001
Completed
Not Applicable

The study of the treatment efficacy in prostate cancer with low dose abiraterone

/A0 sites21 target enrollmentOctober 12, 2021
ConditionsProstate cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
/A
Enrollment
21
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 12, 2021
End Date
July 31, 2020
Last Updated
last year
Study Type
Observational
Sex
Male

Investigators

Sponsor
/A

Eligibility Criteria

Inclusion Criteria

  • 1\. Metastatic prostate cancer patients who are not previously received chemotherapy.
  • 2\. Patients agree to consent for the study.
  • 3\. ECOG performance status 0\-2

Exclusion Criteria

  • 1\. Patient who has prior treatment with abiraterone or enzalutamide.
  • 2\. Patient who has received treatment with drug or other procedure such as
  • radiation therapy and radionuclear Radium 223 method.

Outcomes

Primary Outcomes

Not specified

Similar Trials